Keyphrases
Acute Heart Failure
50%
Adalimumab
12%
Annexin A2 (ANXA2)
50%
Anti-annexin
12%
Anti-annexin A2 Antibodies
31%
Antimicrobial Therapy
11%
Autoantibodies
50%
Autoimmune Disease
50%
Causative Link
10%
Chronic Myeloid Leukemia
50%
Clinical Symptoms
50%
Confidence Interval
37%
Continuous Infusion
43%
COVID-19
28%
Creatinine
18%
Disease Groups
12%
Disease Process
10%
Disease States
10%
Diuretics
31%
Dopamine
50%
Enthesitis
11%
Furosemide
25%
Heart Failure with Preserved Ejection Fraction (HFpEF)
50%
Inflammatory Arthritis
16%
Injection Site Reaction
12%
Intermittent Bolus
31%
Ixekizumab
50%
Low-dose Dopamine
50%
Lyme
17%
Lyme Arthritis
56%
Lyme Disease
90%
Management Approach
10%
Musculoskeletal Ultrasound
50%
Optimal Management
10%
Patient Assessment
15%
Patient Selection
55%
Percent Change
12%
Post-infection
64%
Post-treatment Lyme Disease Syndrome (PTLDS)
100%
Psoriatic Arthritis
50%
Randomized Evaluation
50%
Renal Function Improvement
18%
Safety Efficacy
50%
Safety Patient
50%
Scleritis
50%
Scleroderma
14%
Symptom Burden
20%
Synovitis
11%
Systemic Autoimmune Diseases
20%
Systemic Inflammatory Diseases
20%
Medicine and Dentistry
Acute Decompensated Heart Failure
50%
Adverse Event
10%
Antimicrobial Therapy
5%
Antisynthetase Syndrome
50%
Autoimmune Disease
50%
Bone Erosion
5%
Chronic Myelomonocytic Leukemia
50%
Clinical Finding
5%
Clinician
10%
Continuous Infusion
43%
Creatinine
18%
Disease
29%
Disease Process
10%
Diuresis
6%
Diuretic Agent
31%
Echography
11%
Effusion
5%
Enthesitis
11%
Epileptic Absence
6%
Furosemide
25%
Heart Failure with Preserved Ejection Fraction
50%
Immunosuppressive Treatment
6%
Interstitial Lung Disease
6%
Kidney Function
25%
Linear Regression Analysis
6%
Logistic Regression Analysis
6%
Low Drug Dose
50%
Lyme Arthritis
50%
Lyme Borreliosis
55%
Myositis
6%
Odds Ratio
6%
Physical Examination
5%
Prognostication
10%
Randomized Clinical Trial
6%
Rheumatoid Arthritis
66%
Scleritis
50%
Synovitis
23%
Tendinosis
5%
Tenosynovitis
18%
Treatment Response
11%
Ultrasonography
6%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Heart Failure
50%
Adverse Event
10%
Amoxicillin
11%
Antibiotic Therapy
8%
Antimicrobial Therapy
5%
Arthralgia
5%
Arthritis
22%
Autoimmune Disease
50%
Ceftriaxone
11%
Chronic Myelomonocytic Leukemia
50%
Creatinine
25%
Disease
49%
Disease Duration
5%
Diuretic Agent
41%
Doxycycline
11%
Erythema Chronicum Migrans
14%
Furosemide
33%
Heart Failure with Preserved Ejection Fraction
50%
Infection
8%
Inflammation
5%
Inflammatory Disease
20%
Juvenile Rheumatoid Arthritis
5%
Lyme Arthritis
50%
Lyme Disease
50%
Microorganism
5%
Monarthritis
5%
Randomized Clinical Trial
8%
Scleritis
50%
